Comprehensive interpretation of efgartigimod: Introduction to the drug and review of the marketing process

Efgartigimod is an innovative treatment for generalized myasthenia gravis (gMG) in adults. Myasthenia gravis is an autoimmune disease in which the patient's immune system mistakenly attacks acetylcholine receptors on muscle cells, blocking signal transmission between nerves and muscles, leading to symptoms such as muscle weakness and fatigue.

Through its unique mechanism of action, igamod can precisely regulate the immune system and reduce the production and circulation of pathogenic antibodies. It is used in combination with other myasthenia gravis treatment drugs to provide patients with a more comprehensive and effective treatment plan. Igamod is administered by intravenous infusion, and the treatment cycle and dosage will be individually adjusted according to the patient's specific condition and physical condition.

In clinical studies, igamod has demonstrated significant efficacy and good safety. Patients using igamod have significantly improved muscle strength and daily activities, and the incidence of adverse reactions is low. This result brings new treatment hope to patients with myasthenia gravis, allowing them to better manage the disease and improve their quality of life.

Igamod not only provides an effective treatment option for gMG patients, but also shows potential in the treatment of other autoimmune diseases. As medical research continues to deepen, Igamod is expected to play an important role in more fields and bring good news to more patients.

At present, igamod has been launched in the country and has been successfully included in the scope of medical insurance reimbursement. Among them, adult patients with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR) antibodies can apply for reimbursement when using igamod. The specification of Igamod on the domestic market is 400mg*20ml, and the price is about 4,000 yuan. Domestic patients can go directly to the hospital to buy the drug.

Reference link:https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart